Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from CERo Therapeutics Holdings ( (CERO) ).
CERo Therapeutics Holdings, Inc., a Delaware corporation, entered into a Securities Purchase Agreement on October 14, 2025, with accredited investors to issue up to 9,750 shares of its Series E convertible preferred stock for up to $7 million. This agreement includes the consent of Series C and D stockholders for the issuance of Series E stock, with a reduction in conversion price for Series C and D stocks. The Series E Preferred Stock will rank senior to most other company stocks and includes various rights and protections for investors, such as conversion rights, purchase rights, and redemption options. The company will also enter into a registration rights agreement to facilitate the resale of common stock from these conversions.
The most recent analyst rating on (CERO) stock is a Buy with a $30.00 price target. To see the full list of analyst forecasts on CERo Therapeutics Holdings stock, see the CERO Stock Forecast page.
More about CERo Therapeutics Holdings
Average Trading Volume: 185,992
Technical Sentiment Signal: Sell
Current Market Cap: $3.99M
For a thorough assessment of CERO stock, go to TipRanks’ Stock Analysis page.